155837-14-2Relevant articles and documents
MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER
-
Paragraph 00489-00490, (2021/10/15)
The present disclosure provides compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, L1, R2 B, Q and E are as defined as set forth in
MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER
-
Paragraph 00551-00553, (2021/10/15)
The present disclosure provides compounds represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, V, Q, T, n, p, q, r and s are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.
FGFR INHIBITORS FOR THE TREATMENT OF CANCER
-
, (2020/08/28)
The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.
